Note: This story was updated on Aug. 6, 2025, to correct that proteinase 3 (PR3) and myeloperoxidase (MPO) are the enzymes targeted by AAV-causing antibodies. People with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis have elevated levels of certain immune-related proteins in their blood, a new study from Sweden reports. However, different…
Long-term treatment with Nucala (mepolizumab) is safe and effective in people with eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated vasculitis (AAV), according to a meta-analysis of eight studies. After nearly two years of treatment, more than half of EGPA patients achieved remission, meaning they had…
Ratios of different kinds of blood cells, reflecting inflammation and immune activity, may be a cheap and efficient tool to aid in the diagnosis of ANCA-associated vasculitis (AAV), and in predicting disease activity, a new study from China reports. “While not standalone diagnostic tools, these markers offer valuable support…
Some people with ANCA-associated vasculitis (AAV) have elevated biomarkers suggesting activation of the immune system’s complement cascade, which is known to contribute to AAV, even when they’re in disease remission, a study showed. While these biomarkers did not appear to be associated with an increased risk of future disease…
The most common neurological symptoms of ANCA-associated vasculitis (AAV) among patients in a single center in Columbia — regardless of disease type — were headache and objective signs of damage to nerves outside the brain and spinal cord, a study showed. That said, the researchers found a vast array…
In adults with ANCA-associated vasculitis (AAV), the amount of TWEAK protein in urine was about 50% as high when their disease was active as after six months of treatment, making it a useful biomarker for tracking disease activity, according to a new study from Sweden. The study further found…
Vertex Pharmaceuticals has signed a license agreement with Ono Pharmaceutical to develop and market povetacicept — a B-cell-targeting candidate for treating ANCA-associated vasculitis (AAV) and other autoimmune diseases driven by self-reactive antibodies and marked by signs or symptoms of kidney involvement — in Japan and South Korea.
Updated treatment guidelines from the British Society for Rheumatology favor rituximab over cyclophosphamide for active, relapsing ANCA-associated vasculitis (AAV), and set a standard maintenance treatment period of about 2-4 years after the disease has entered remission, or is determined to be well controlled. These recommendations are part of…
The selective immunosuppressive medication abatacept failed to significantly prevent treatment failure relative to a placebo in people with relapsing, non-severe granulomatosis with polyangiitis (GPA) taking part in a Phase 3 clinical trial, new data show. In addition to failing to meet this main goal of the study — called…
Up to two years of treatment with AstraZeneca’s Fasenra (benralizumab) helped adults with eosinophilic granulomatosis with polyangiitis (EGPA) that’s difficult to treat achieve and maintain disease remission, while reducing or eliminating the need for oral corticosteroids. That’s according to combined data from the completed head-to-head portion and the…
Get regular updates to your inbox.
